Rhumbline Advisers Adverum Biotechnologies, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.68 - $1.59 $1,997 - $4,669	2,937 New	2,937 $4,000
Q2 2022 Aug 11, 2022	SELL	$0.81 - $1.34 $96,560 - $159,741	-119,210 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.23 - $1.95 $11,887 - $18,846	-9,665 Reduced 7.5%	119,210 $156,000
Q4 2021 Feb 10, 2022	SELL	$1.74 - $2.4 $495 - $684	-285 Reduced 0.22%	128,875 $227,000
Q3 2021 Nov 12, 2021	BUY	$2.08 - $3.6 $4,388 - $7,596	2,110 Added 1.66%	129,160 $280,000
Q2 2021 Aug 05, 2021	BUY	$3.36 - $10.56 $59,149 - $185,898	17,604 Added 16.08%	127,050 $445,000
Q1 2021 May 06, 2021	SELL	$9.26 - $14.36 $81,441 - $126,296	-8,795 Reduced 7.44%	109,446 $1.08 Million
Q4 2020 Feb 10, 2021	BUY	$9.84 - $14.26 $84,584 - $122,578	8,596 Added 7.84%	118,241 $1.28 Million
Q3 2020 Nov 12, 2020	SELL	$10.3 - $21.64 $89,898 - $188,873	-8,728 Reduced 7.37%	109,645 $1.13 Million
Q2 2020 Aug 13, 2020	BUY	$8.53 - $25.64 $294,225 - $884,400	34,493 Added 41.12%	118,373 $2.47 Million
Q1 2020 May 06, 2020	BUY	$7.98 - $16.32 $85,098 - $174,036	10,664 Added 14.57%	83,880 $820,000
Q4 2019 Feb 05, 2020	BUY	$5.12 - $12.22 $3,440 - $8,211	672 Added 0.93%	73,216 $843,000
Q3 2019 Oct 23, 2019	SELL	$5.24 - $15.89 $655 - $1,986	-125 Reduced 0.17%	72,544 $395,000
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $22,230 - $51,828	-4,359 Reduced 5.66%	72,669 $864,000
Q1 2019 May 01, 2019	SELL	$3.03 - $6.02 $2,627 - $5,219	-867 Reduced 1.11%	77,028 $404,000
Q4 2018 Jan 31, 2019	BUY	$2.87 - $5.92 $66,230 - $136,615	23,077 Added 42.1%	77,895 $245,000
Q3 2018 Nov 07, 2018	SELL	$4.5 - $7.6 $1,125 - $1,900	-250 Reduced 0.45%	54,818 $332,000
Q2 2018 Aug 06, 2018	BUY	$5.3 - $6.9 $291,860 - $379,969	55,068 New	55,068 $292,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.4 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$74,418
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$5,451
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account